AU2003238874A1 - Bisindolyl-maleimid derivatives as kinase inhibitors - Google Patents
Bisindolyl-maleimid derivatives as kinase inhibitors Download PDFInfo
- Publication number
- AU2003238874A1 AU2003238874A1 AU2003238874A AU2003238874A AU2003238874A1 AU 2003238874 A1 AU2003238874 A1 AU 2003238874A1 AU 2003238874 A AU2003238874 A AU 2003238874A AU 2003238874 A AU2003238874 A AU 2003238874A AU 2003238874 A1 AU2003238874 A1 AU 2003238874A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- group
- aryl
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38593502P | 2002-06-05 | 2002-06-05 | |
| US60/385,935 | 2002-06-05 | ||
| PCT/US2003/017569 WO2003104222A1 (en) | 2002-06-05 | 2003-06-04 | Bisindolyl-maleimid derivatives as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003238874A1 true AU2003238874A1 (en) | 2003-12-22 |
Family
ID=29736126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003238874A Abandoned AU2003238874A1 (en) | 2002-06-05 | 2003-06-04 | Bisindolyl-maleimid derivatives as kinase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6987110B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1513830A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005531609A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050008787A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1671694A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003238874A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0311821A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2488602A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR7606A (cg-RX-API-DMAC7.html) |
| IL (1) | IL165515A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04012188A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20045699L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2004135382A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003104222A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0116468A (pt) * | 2000-12-08 | 2004-06-29 | Ortho Mcneil Pharm Inc | Compostos de pirrolina substituìda por indazolila como inibidores de cinase |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| CA2485527A1 (en) * | 2002-05-08 | 2003-11-20 | Janssen Pharmaceutica N.V. | Substituted pyrroline kinase inhibitors |
| ES2312785T3 (es) * | 2002-06-05 | 2009-03-01 | Janssen Pharmaceutica Nv | Pirrolinas sustituidas utiles como inhibidores de quinasa. |
| CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| AU2002951253A0 (en) * | 2002-09-06 | 2002-09-19 | Medvet Science Pty. Ltd. | A method of modulating cellular activity |
| JP2006521386A (ja) * | 2003-03-27 | 2006-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤である置換ピロリン |
| US7439363B2 (en) * | 2003-06-13 | 2008-10-21 | Janssen Parmaceutica N.V. | Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors |
| US20080050314A1 (en) * | 2004-02-26 | 2008-02-28 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b) |
| WO2005095983A1 (en) * | 2004-03-04 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with protein kinase c, gamma (prkcg) |
| RU2413511C2 (ru) * | 2004-04-08 | 2011-03-10 | Новартис Аг | Ингибиторы протеинкиназы с, предназначенные для лечения аутоиммунных заболеваний и отторжения трансплантата |
| US20070232658A1 (en) * | 2004-04-08 | 2007-10-04 | Jurgen Wagner | Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction |
| CA2567377A1 (en) * | 2004-05-21 | 2006-03-09 | The Texas A & M University System | Inhibition of atherosclerosis by diindolylmethane analogs |
| EP1662259A1 (en) * | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| JP2009500297A (ja) * | 2005-06-08 | 2009-01-08 | セントカー・インコーポレーテツド | 眼の変性についての細胞療法 |
| EP2246346B1 (en) | 2005-07-11 | 2012-10-24 | Novartis AG | Indolylmaleimide derivatives as protein kinase inhibitors |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| WO2007041195A2 (en) * | 2005-09-29 | 2007-04-12 | Janssen Pharmaceutica N.V. | Macroheterocylic compounds as kinase inhibitors |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20090324610A1 (en) * | 2006-04-25 | 2009-12-31 | Kyushu Univeristy, National University Corporation | Gene associated with arteriosclerotic disease, and use thereof |
| US8741643B2 (en) * | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2008063278A (ja) * | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | 1−ピリジン−4−イル−インドール類の製造方法 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US9080145B2 (en) * | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| RU2473685C2 (ru) | 2007-07-31 | 2013-01-27 | Лайфскен, Инк. | Дифференцировка человеческих эмбриональных стволовых клеток |
| CN107574142B (zh) | 2007-11-27 | 2021-07-06 | 生命扫描有限公司 | 人胚胎干细胞的分化 |
| FR2927075A1 (fr) * | 2008-02-04 | 2009-08-07 | Centre Nat Rech Scient | Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes |
| BRPI0908033A2 (pt) | 2008-02-21 | 2015-08-04 | Centocor Ortho Biotech Inc | Método placas de superfície modificada e composições para adesão, cultura e desprendimento de célula |
| US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
| CN108486040A (zh) * | 2008-06-30 | 2018-09-04 | 詹森生物科技公司 | 多能干细胞的分化 |
| CA2729121C (en) | 2008-06-30 | 2019-04-09 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
| US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
| JP2012507289A (ja) | 2008-10-31 | 2012-03-29 | ヤンセン バイオテツク,インコーポレーテツド | ヒト胚性幹細胞の膵内分泌系への分化 |
| EP2346988B1 (en) * | 2008-10-31 | 2017-05-31 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
| MX2011005288A (es) | 2008-11-20 | 2011-06-01 | Centocor Ortho Biotech Inc | Celulas madre pluripotentes en microportadores. |
| CA2744227C (en) * | 2008-11-20 | 2018-10-02 | Centocor Ortho Biotech Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| RU2540016C2 (ru) | 2009-07-20 | 2015-01-27 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека |
| EP2456858B1 (en) | 2009-07-20 | 2018-08-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| EP2456862A4 (en) | 2009-07-20 | 2013-02-27 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
| PH12012500818A1 (en) * | 2009-10-29 | 2019-11-29 | Janssen Biotech Inc | Pluripotent stem cells |
| DK2516625T3 (da) | 2009-12-23 | 2024-09-09 | Janssen Biotech Inc | Differentiering af humane embryonale stamceller |
| RU2664864C1 (ru) * | 2009-12-23 | 2018-08-23 | Янссен Байотек, Инк. | Способы увеличения экспрессии ngn3 и nkx6.1 в эндокринных клетках поджелудочной железы |
| AU2011223900A1 (en) * | 2010-03-01 | 2012-09-13 | Janssen Biotech, Inc. | Methods for purifying cells derived from pluripotent stem cells |
| AU2011250912A1 (en) | 2010-05-12 | 2012-11-22 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| KR101836850B1 (ko) | 2010-08-31 | 2018-03-09 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| CN103221536B (zh) | 2010-08-31 | 2016-08-31 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| WO2012030540A2 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| ES2387359B1 (es) * | 2011-02-25 | 2013-08-01 | Consejo Superior De Investigaciones Científicas (Csic) | Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos |
| RU2705001C2 (ru) | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки |
| MX354775B (es) | 2012-03-07 | 2018-03-20 | Janssen Biotech Inc | Medios definidos para la expansion y el mantenimiento de celulas madre pluripotentes. |
| CN104334719B (zh) | 2012-06-08 | 2018-02-13 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌细胞的分化 |
| KR102084561B1 (ko) | 2012-12-31 | 2020-03-04 | 얀센 바이오테크 인코포레이티드 | 췌장 내분비 세포로의 분화를 위한 공기-액체 계면에서의 인간 배아 줄기세포의 배양 |
| MX2015008578A (es) | 2012-12-31 | 2015-09-07 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9. |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| DK2938722T3 (da) | 2012-12-31 | 2022-02-14 | Janssen Biotech Inc | Suspension og klyngedannelse af humane pluripotente celler til differentiering til endokrine pankreasceller |
| SG11201609473XA (en) | 2014-05-16 | 2016-12-29 | Janssen Biotech Inc | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
| WO2017180361A1 (en) | 2016-04-14 | 2017-10-19 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells to intestinal midgut endoderm cells |
| CN105777751B (zh) * | 2016-04-26 | 2018-12-11 | 浙江工业大学 | 一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用 |
| WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ280738B6 (cs) | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
| GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| EP1449529B1 (en) * | 1993-12-23 | 2010-01-27 | Eli Lilly And Company | Protein Kinase C Inhibitors |
| JP3258334B2 (ja) | 1996-03-20 | 2002-02-18 | イーライ・リリー・アンド・カンパニー | インドリルマレイミドの合成 |
| SE9603283D0 (sv) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| AU2548699A (en) * | 1998-02-23 | 1999-09-06 | Rei Asakai | Cell death inhibitors |
| HUP0103381A3 (en) | 1998-07-30 | 2002-07-29 | Japan Tobacco Inc | Disubstituted maleimide compounds and medicinal utilization thereof and the pharmaceutical compositions containing the same |
| JP2002527419A (ja) | 1998-10-08 | 2002-08-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Gsk−3阻害物質としてのピロール−2,5−ジオン類 |
| CA2417277A1 (en) | 2000-07-27 | 2002-02-07 | F. Hoffmann-La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta. |
| CN1253449C (zh) | 2000-11-07 | 2006-04-26 | 诺瓦提斯公司 | 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物 |
-
2003
- 2003-06-04 JP JP2004511292A patent/JP2005531609A/ja not_active Withdrawn
- 2003-06-04 WO PCT/US2003/017569 patent/WO2003104222A1/en not_active Ceased
- 2003-06-04 KR KR10-2004-7019678A patent/KR20050008787A/ko not_active Withdrawn
- 2003-06-04 EP EP03734389A patent/EP1513830A1/en not_active Withdrawn
- 2003-06-04 BR BR0311821-5A patent/BR0311821A/pt not_active IP Right Cessation
- 2003-06-04 AU AU2003238874A patent/AU2003238874A1/en not_active Abandoned
- 2003-06-04 MX MXPA04012188A patent/MXPA04012188A/es unknown
- 2003-06-04 CN CNA038184788A patent/CN1671694A/zh active Pending
- 2003-06-04 CA CA002488602A patent/CA2488602A1/en not_active Abandoned
- 2003-06-04 US US10/454,069 patent/US6987110B2/en not_active Expired - Fee Related
- 2003-06-04 RU RU2004135382/04A patent/RU2004135382A/ru not_active Application Discontinuation
-
2004
- 2004-12-02 IL IL16551504A patent/IL165515A0/xx unknown
- 2004-12-06 CR CR7606A patent/CR7606A/es unknown
- 2004-12-29 NO NO20045699A patent/NO20045699L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050008787A (ko) | 2005-01-21 |
| US20040059113A1 (en) | 2004-03-25 |
| IL165515A0 (en) | 2006-01-15 |
| JP2005531609A (ja) | 2005-10-20 |
| US6987110B2 (en) | 2006-01-17 |
| MXPA04012188A (es) | 2005-07-25 |
| RU2004135382A (ru) | 2005-06-27 |
| BR0311821A (pt) | 2005-04-05 |
| WO2003104222A1 (en) | 2003-12-18 |
| CN1671694A (zh) | 2005-09-21 |
| NO20045699L (no) | 2005-01-28 |
| EP1513830A1 (en) | 2005-03-16 |
| CR7606A (es) | 2009-01-16 |
| CA2488602A1 (en) | 2003-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6987110B2 (en) | Substituted pyrrolines as kinase inhibitors | |
| US7759380B2 (en) | Substituted pyrrolines as kinase inhibitors | |
| EP1654255B1 (en) | Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors | |
| EP1362047B1 (en) | Indazolyl-substituted pyrroline compounds as kinase inhibitors | |
| US20090093634A1 (en) | Substituted pyrroline kinase inhibitors | |
| HK1057370B (en) | Indazolyl-substituted pyrroline compounds as kinase inhibitors | |
| MXPA05013655A (en) | Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |